The #ACR20 Great Debate is on! One issue point is lab monitoring on TNF vs JAK. What's your take? @RheumNow

Who can have sustained DMARD-free remission (SDFR)? Abst#0479 says early DAS response after DMARD initiation in ACPA-negative patients #ACR20 @RheumNow. Who do you try for DMARD-free intervals? https://t.co/EOfPt4YQAu

Perform (annual) skin exams in patients in MTX based on discovery of a new adverse effect signal with use of low dose MTX (median dose 15 mg/wk) with a NNH of 167! Screening 160 RA patients on MTX will identify 1 skin Ca. Amazing #ACR20 Year in Review by @JYazdanyMD. @RheumNow https://t.co/hUCzKSYZnB

Abst#0142 at #ACR20, a post-hoc analysis of FINCH2, shows that filgotinib (FIL)(Jak1-i) + csDMARD improved the degree of activity impairment in a clinically relevant manner compared to placebo + csDMARD in pts w/ inadequate response to bDMARD . @RheumNow https://t.co/6M42LUVuht

ACPA in patients with RA are multireactive. How can one antibody bind to so many proteins? ACPA recognize very small linear epitopes shared by many posttranslationally modified proteins. 2F012. Antibodies in RA. #ACR20. <TK https://t.co/OUqshFoxSb

#hydroxychloroquine is not a ‘cutie’ drug. E Park et al showed that HCQ does not increase QT interval in RA & SLE patients including if on other meds that may affect QT but known heart disease excluded from study #ACR20 #ACR2020 @RheumNow abstr#432 @CRASCRRheum https://t.co/FGVPknmj5q

Sustained DMARD-free remission (SFDR) seen in ACPA- RA pts; DAS levels at 4mos. predictive for SFDR. ACPA+ pts no relation w/ SFDR & DAS course @RheumNow #ACR20 Abstr#479 #ACRbest https://t.co/kko4tO7s1Y

Large data from Japanese Ninja database in abst#0183 shows incidence of malignancies in Japanese RA patients similar to Japanese gen pop. Comparable in patients exposed and unexposed to biologics/JAKs. #ACR20 @RheumNow

Great debate by Dr. Weinblatt and Dr. Strand on JAKinibs vs TNFi in RA! How long do you tx with JAKinibs before calling it a failure? @RheumNow #ACR20 #ACRbest

Abst#0135 at #ACR20 illustrates the drivers of patient satisfaction per a survey of 374 U.S. pts. The biggest obstacles to managing RA are pain (80%), fatigue (72%), & depression/anxiety (51%), but only 51% of pts feel that these are addressed. @RheumNow https://t.co/I2ac2T2TOA